BMY

In the past six months (April 2026 to October 2026), Bristol Myers Squibb reported strong Q1 FY26 earnings with EPS of $1.58 and revenue of $11.49 billion, both exceeding estimates. Q2 FY26 earnings also surpassed expectations, with sales up 5.7% to $12.97 billion and non-GAAP profit of $2.04 per share, leading to raised full-year 2026 guidance. The FDA approved an expanded indication for CAMZYOS in September 2026 for symptomatic obstructive hypertrophic cardiomyopathy. The company also reported positive clinical trial results, including Phase 2 data for arlo-cel therapy in multiple myeloma, two-year Phase 3 data for Sotyktu in psoriatic arthritis, and encouraging topline Phase 3 results for Zenbexus in multiple myeloma. The stock hit a 3-year high in August 2026 but subsequently declined to a 4-week low in September 2026 and a 10-week low in October 2026.